Cover Image
市場調查報告書

氣喘治療藥的美國市場:2015年∼2019年

Asthma Drugs Market in the US 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 332612
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
Back to Top
氣喘治療藥的美國市場:2015年∼2019年 Asthma Drugs Market in the US 2015-2019
出版日期: 2015年06月10日 內容資訊: 英文 103 Pages
簡介

美國的氣喘治療藥市場預測在2014年∼2019年這段期間將以4.64%的速度成長。

本報告提供美國的氣喘治療藥市場相關之調查分析,提供您市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,並彙整主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 提供產品

第4章 產品簡介

  • Accolate
  • Pulmicort
  • Symbicort
  • Xolair
  • Advair
  • Anoro Ellipta
  • Arnuity Ellipta
  • Breo Ellipta
  • Flovent
  • Serevent
  • Ventolin
  • Asmanex
  • Foradil
  • Dulera
  • Singulair

第5章 市場調查手法

  • 市場調查流程
  • 調查手法

第6章 簡介

第7章 疾病概要

  • 疾病的認識
  • 症狀
  • 病理學
    • 呼吸道發炎
    • 呼吸道重塑
  • 流行病學
  • 診斷
  • 管理

第8章 開發平台的組合

第9章 市場形勢

  • 市場概要
  • 市場規模·預測
  • 波特的五力分析

第10章 市場區隔:各類藥物

第11章 支氣管擴張劑

  • 美國的支氣管擴張劑市場
    • 市場概要
    • 市場規模·預測

第12章 LABA/ICS混合藥

第13章 免疫抑制劑

第14章 白三烯拮抗劑

第15章 肥大細胞穩定劑

第16章 購買標準

第17章 推動市場成長要素

第18章 成長推動因素與其影響

第19章 市場課題

第20章 成長推動因素與課題的影響

第21章 市場趨勢

第22章 趨勢與其影響

第23章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他·未來的有潛力的供應商

第24章 主要供應商分析

  • AstraZeneca
    • 主要資料
    • 產業概要
    • 產業區分:各收益
    • 銷售額:各地區
    • 產業策略
    • 主要的發展
    • SWOT分析
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck

第25章 相關報告

圖表

目錄
Product Code: IRTNTR6049

About asthma

Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy.

Technavio's analysts forecast the asthma drugs market in the US to grow at a CAGR of 4.64% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the asthma drugs market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sale of various classes of drugs used to treat asthma, which include:

  • Bronchodilators
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Immunosuppressants
  • Combination of LABA/ICS

Technavio's report, Asthma Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck

Other Prominent Vendors

  • Abbott Laboratories
  • Addex Therapeutics
  • Alkermes
  • AstraZeneca
  • Aurobindo Pharma
  • Avanir Pharmaceuticals
  • Cerecor
  • Chugai Pharmaceutical
  • Dart NeuroScience
  • Dr. Reddy's Laboratories
  • Edgemont Pharmaceuticals
  • E-Therapeutics
  • Euthymics
  • Evotec
  • F. Hoffmann-La Roche
  • Fabre Kramer
  • Gedeon Richter
  • H. Lundbeck
  • Intra-Cellular Therapies
  • Janssen Pharmaceuticals
  • Lupin
  • Luye Pharma
  • MSI Methylation Sciences
  • Naurex
  • Neuralstem
  • Novartis
  • Opko Health
  • Otsuka Pharmaceutical
  • Pierre Fabre
  • Shire
  • SK Biopharmaceuticals
  • Somerset Pharmaceuticals
  • Sun Pharmaceutical
  • Sunovion Pharmaceuticals
  • Suven
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • Torrent Pharmaceuticals
  • Valeant Pharmaceuticals

Market driver

  • Rise in disease prevalence
  • For a full, detailed list, view our report

Market challenge

  • Unknown disease etiology
  • For a full, detailed list, view our report

Market trend

  • Popularity of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market overview
  • 03.2. Product offerings

04. Product Profiles

    • 04.1.1. Accolate
    • 04.1.2. Pulmicort
    • 04.1.3. Symbicort
    • 04.1.4. Xolair
    • 04.1.5. Advair
    • 04.1.6. Anoro Ellipta
    • 04.1.7. Arnuity Ellipta
    • 04.1.8. Breo Ellipta
    • 04.1.9. Flovent
    • 04.1.10. Serevent
    • 04.1.11. Ventolin
    • 04.1.12. Asmanex
    • 04.1.13. Foradil
    • 04.1.14. Dulera
    • 04.1.15. Singulair

05. Market Research Methodology

  • 05.1. Market research process
  • 05.2. Research methodology

06. Introduction

07. Disease Overview

  • 07.1. Understanding the disease
  • 07.2. Symptoms
  • 07.3. Pathophysiology
    • 07.3.1. Airway inflammation
    • 07.3.2. Airway remodeling
  • 07.4. Epidemiology
  • 07.5. Diagnosis
  • 07.6. Management

08. Pipeline Portfolio

09. Market Landscape

  • 09.1. Market overview
  • 09.2. Market size and forecast
  • 09.3. Five forces analysis

10. Market Segmentation by Class of Drug

11. Bronchodilators

  • 11.1. Bronchodilators market in US
    • 11.1.1. Market overview
    • 11.1.2. Market size and forecast

12. Combination of LABA/ICS

  • 12.1. Combination of LABA/ICS market in US
    • 12.1.1. Market overview
    • 12.1.2. Market size and forecast

13. Immunosuppressants

  • 13.1. Immunosuppressants market in US
    • 13.1.1. Market overview
    • 13.1.2. Market size and forecast

14. Leukotriene Antagonists

  • 14.1. Leukotriene antagonists market in US
    • 14.1.1. Market overview
    • 14.1.2. Market size and forecast

15. Mast Cell Stabilizers

  • 15.1. Mast cell stabilizers market in US
    • 15.1.1. Market overview
    • 15.1.2. Market size and forecast

16. Buying Criteria

17. Market Growth Drivers

18. Drivers and their Impact

19. Market Challenges

20. Impact of Drivers and Challenges

21. Market Trends

22. Trends and Their Impact

23. Vendor Landscape

  • 23.1. Competitive scenario
    • 23.1.1. Key news
    • 23.1.2. Mergers and acquisitions
  • 23.2. Market share analysis 2014
    • 23.2.1. GlaxoSmithKline
    • 23.2.2. AstraZeneca
    • 23.2.3. F. Hoffmann-La Roche
    • 23.2.4. Merck
  • 23.3. Other and future prominent vendors

24. Key Vendor Analysis

  • 24.1. AstraZeneca
    • 24.1.1. Key facts
    • 24.1.2. Business overview
    • 24.1.3. Business segmentation by revenue 2013
    • 24.1.4. Business segmentation by revenue 2011-2013
    • 24.1.5. Sales by geography
    • 24.1.6. Business strategy
    • 24.1.7. Key developments
    • 24.1.8. SWOT analysis
  • 24.2. F. Hoffmann-La Roche
    • 24.2.1. Key facts
    • 24.2.2. Business overview
    • 24.2.3. Business segmentation
    • 24.2.4. Business segmentation by revenue 2012 and 2013
    • 24.2.5. Sales by geography
    • 24.2.6. Business strategy
    • 24.2.7. Key information
    • 24.2.8. SWOT analysis
  • 24.3. GlaxoSmithKline
    • 24.3.1. Key facts
    • 24.3.2. Business overview
    • 24.3.3. Business segmentation by revenue 2014
    • 24.3.4. Business segmentation by revenue 2013 and 2014
    • 24.3.5. Geographical segmentation by revenue 2014
    • 24.3.6. Business strategy
    • 24.3.7. Recent developments
    • 24.3.8. SWOT analysis
  • 24.4. Merck
    • 24.4.1. Key facts
    • 24.4.2. Business overview
    • 24.4.3. Business segmentation by revenue 2013
    • 24.4.4. Business segmentation by revenue 2012 and 2013
    • 24.4.5. Sales by geography
    • 24.4.6. Business strategy
    • 24.4.7. Key developments
    • 24.4.8. SWOT analysis

25. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market research methodology
  • Exhibit 2: Major diagnostic procedures for asthma
  • Exhibit 3: Asthma drugs market in US 2014-2019 ($ millions)
  • Exhibit 4: Segmentation of asthma drugs market in US by class of drug
  • Exhibit 5: Segmentation of asthma drugs market in US by class of drug 2014
  • Exhibit 6: Segmentation of asthma drugs market in US by class of drug 2019
  • Exhibit 7: Bronchodilators market in US 2014-2019 ($ millions)
  • Exhibit 8: Combination of LABA/ICS market in US 2014-2019 ($ millions)
  • Exhibit 9: Immunosuppressants market in US 2014-2019 ($ millions)
  • Exhibit 10: Leukotriene antagonists market in US 2014-2019 ($ millions)
  • Exhibit 11: Mast cell stabilizers market in US 2014-2019 ($ millions)
  • Exhibit 12: Major drivers of asthma drugs market in US
  • Exhibit 13: Major challenges in asthma drugs market in US
  • Exhibit 14: Major trends in asthma drugs market in US
  • Exhibit 15: Prescription chart of popular asthma drugs in US 2013
  • Exhibit 16: Market share analysis 2014
  • Exhibit 17: YoY growth rate of major asthma drugs 2011-2014 ($ millions)
  • Exhibit 18: GlaxoSmithKline: Global and US revenue of Breo Ellipta 2013 and 2014 ($ millions)
  • Exhibit 19: GlaxoSmithKline: Global revenue and YoY growth rate of Ventolin 2011-2014 ($ millions)
  • Exhibit 20: GlaxoSmithKline: US revenue and YoY growth rate of Ventolin 2011-2014 ($ millions)
  • Exhibit 21: GlaxoSmithKline: Global revenue and YoY growth rate of Flovent 2011-2014 ($ millions)
  • Exhibit 22: GlaxoSmithKline: US revenue and YoY growth rate of Flovent 2011-2014 ($ millions)
  • Exhibit 23: GlaxoSmithKline: Global revenue and YoY growth rate of Advair 2011-2014 ($ millions)
  • Exhibit 24: GlaxoSmithKline: US revenue and YoY growth rate of Advair 2011-2014 ($ millions)
  • Exhibit 25: GlaxoSmithKline: Global revenue and YoY growth rate of Serevent 2011-2014 ($ millions)
  • Exhibit 26: GlaxoSmithKline: US revenue and YoY growth rate of Serevent 2011-2014 ($ millions)
  • Exhibit 27: GlaxoSmithKline: US revenue of key asthma drugs 2011-2014 ($ millions)
  • Exhibit 28: AstraZeneca: Global revenue and YoY growth rate of Pulmicort 2011-2014 ($ millions)
  • Exhibit 29: AstraZeneca: US revenue and YoY growth rate of Pulmicort 2011-2014 ($ millions)
  • Exhibit 30: AstraZeneca: Global revenue and YoY growth rate of Symbicort 2011-2014 ($ millions)
  • Exhibit 31: AstraZeneca: US revenue and YoY growth rate of Symbicort 2011-2014 ($ millions)
  • Exhibit 32: AstraZeneca: US revenue of key asthma drugs 2011-2014 ($ millions)
  • Exhibit 33: F. Hoffmann-La Roche: Global revenue and YoY growth rate of Xolair 2011-2014 ($ millions)
  • Exhibit 34: Merck: Global revenue and YoY growth rate of Asmanex 2011-2013 ($ millions)
  • Exhibit 35: Merck: Global revenue and YoY growth rate of Dulera 2011-2014 ($ millions)
  • Exhibit 36: Merck: Global revenue and YoY growth rate of Singulair 2011-2014 ($ millions)
  • Exhibit 37: AstraZeneca: Business segmentation by revenue 2013
  • Exhibit 38: AstraZeneca: Business segmentation by revenue 2011-2013 ($ millions)
  • Exhibit 39: AstraZeneca: Sales by geography 2013
  • Exhibit 40: Business segmentation of F. Hoffmann-La Roche 2013
  • Exhibit 41: F. Hoffmann-La Roche: Business segmentation by revenue 2012 and 2013
  • Exhibit 42: F. Hoffmann-La Roche: Sales by geography 2013 (pharmaceuticals division)
  • Exhibit 43: F. Hoffmann-La Roche: Sales by geography 2013 (diagnostics division)
  • Exhibit 44: GlaxoSmithKline: Business segmentation by revenue 2014
  • Exhibit 45: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 46: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 47: Merck: Business segmentation by revenue 2013
  • Exhibit 48: Merck: Business segmentation by revenue 2012 and 2013 ($ billions)
  • Exhibit 49: Merck: Sales by geography 2013
Back to Top